{"id":"W3088227025","doi":"10.1016/j.annonc.2020.08.2274","title":"LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Population; Clinical endpoint; Oncology; Tolerability; Surgery; Urology; Clinical trial; Adverse effect; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005373863,0.0006881636,0.0007984015,0.0003244708,0.0003303832,0.0007073898,0.0005904034,0.0005332276,0.003443037],"category_scores_gemma":[0.0003687438,0.0002230956,0.0008831746,0.0003087175,0.0002997815,0.0005022319,0.0003206564,0.003036767,0.0007685184],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008538069,"about_ca_system_score_gemma":0.000786176,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001890756,"about_ca_topic_score_gemma":0.006210485,"domain_scores_codex":[0.9998088,0.00006252622,0.00001004675,0.00002345315,0.00002677859,0.00006840246],"domain_scores_gemma":[0.9998647,0.00002787087,0.00001120786,0.00001158114,0.000007796074,0.00007684995],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.107426,0.04374221,0.007825741,0.0009187448,0.001889586,0.001835076,0.0003148719,0.006392613,0.07412466,0.001118839,0.0134316,0.74098],"study_design_scores_gemma":[0.1809583,0.5411717,0.0920912,0.0003582925,0.002690013,0.006830278,0.0003740285,0.01910903,0.05900333,0.002008721,0.09523009,0.0001749921],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9717844,0.009485042,0.001003982,0.001808005,0.000305571,0.0008679829,0.001168706,0.0002197192,0.01335659],"genre_scores_gemma":[0.9818568,0.004914649,0.002472142,0.001005683,0.0001508325,0.000376275,0.002182523,0.00004161996,0.006999509],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003443037,"threshold_uncertainty_score":0.01151812,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1887182812101126,"score_gpt":0.4233166752367792,"score_spread":0.2345983940266666,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}